newsfilter
← Latest News
GlobeNewswire·

Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR

- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceutica